Depressão

Cognitive dysfunction in major depressive disorder

The principal aim of this review is to highlight recent advances in our understanding of cognitive dysfunction in major depressive disorder (MDD). We review new assessment and treatment approaches, in which cognition and associated psychosocial dysfunction are considered primary outcomes. Current work suggests that cognitive dysfunction reduces occupational productivity, and interferes broadly with domains of day-to-day and social […]

Cognitive dysfunction in major depressive disorder Read More »

Depressive symptoms and disorders in type 2 diabetes mellitus

Recent studies reviewed indicate an increasing trend of both major and minor depression in patients with diabetes. Depression is also reported to be persistent and chronic in diabetes patients. There is a bidirectional link between depression and diabetes. Diabetes-related distress independently increases the diabetes-related complications. Collaborative care is both applicable and helpful in managing depression in diabetes.  Leer texto

Depressive symptoms and disorders in type 2 diabetes mellitus Read More »

Inflammation and depression but where does the inflammation come from?

The advent of innovative theories about the pathophysiology of psychiatric disorders has ushered in a new era on the basis of the role of the immune system and inflammation in mediating depression in its multifaceted manifestations. Extensive studies have confirmed the proinflammatory status in depression and causal relationships with neurotransmitter dysregulation. Equally importantly the role

Inflammation and depression but where does the inflammation come from? Read More »

Inflammation and depression but where does the inflammation come from?

The advent of innovative theories about the pathophysiology of psychiatric disorders has ushered in a new era on the basis of the role of the immune system and inflammation in mediating depression in its multifaceted manifestations. Extensive studies have confirmed the proinflammatory status in depression and causal relationships with neurotransmitter dysregulation. Equally importantly the role

Inflammation and depression but where does the inflammation come from? Read More »

Depression: more treatment but no drop in prevalence: how effective is treatment? And can we do better?

To reduce prevalence, it is essential to narrow the treatment gaps, provide timely interventions and high- quality treatment, eradicate waiting lists, prescribe antidepressants more cautiously and better managed, consider psychological alternatives, and provide more psychosocial treatment in primary care with physician-assistants. In addition, research is needed on long-term outcome of different treatment modalities, and least

Depression: more treatment but no drop in prevalence: how effective is treatment? And can we do better? Read More »

Neurofilament light protein as a biomarker in depression and cognitive function

Axonal damage is implicated in the neuropathology of depression and cognitive dysfunction. Consequently, neurofilament light protein is an emerging biomarker with potential in depression and cognitive function. Results are more consistent for cognition, requiring more research to assess neurofilament light protein in depression as well as other psychiatric disorders. Future longitudinal studies are necessary to

Neurofilament light protein as a biomarker in depression and cognitive function Read More »

Neurofilament light protein as a biomarker in depression and cognitive function

Axonal damage is implicated in the neuropathology of depression and cognitive dysfunction. Consequently, neurofilament light protein is an emerging biomarker with potential in depression and cognitive function. Results are more consistent for cognition, requiring more research to assess neurofilament light protein in depression as well as other psychiatric disorders. Future longitudinal studies are necessary to

Neurofilament light protein as a biomarker in depression and cognitive function Read More »

Depression: more treatment but no drop in prevalence: how effective is treatment? And can we do better?

To reduce prevalence, it is essential to narrow the treatment gaps, provide timely interventions and high- quality treatment, eradicate waiting lists, prescribe antidepressants more cautiously and better managed, consider psychological alternatives, and provide more psychosocial treatment in primary care with physician-assistants. In addition, research is needed on long-term outcome of different treatment modalities, and least

Depression: more treatment but no drop in prevalence: how effective is treatment? And can we do better? Read More »

Iniciar Sesión

Logo_azul

Regístrate